Pulmonary Arterial Hypertension Treatment Market Poised to Exceed US$ 6.6 Billion by 2028-FMI Study

The pulmonary arterial hypertension (PAH) treatment market stands as a beacon of hope for individuals grappling with this rare but serious condition that affects the heart and lungs. PAH involves abnormally high blood pressure in the arteries that connect the heart and lungs, leading to reduced blood flow and strain on the heart. The treatment landscape for …